Wed, 04 Dec 2024
Zepbound's greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of the weight loss drug market.
Terms of Use | Privacy Policy | Manage Cookies+ | Ad Choices | Accessibility & CC| About | Newsletters | Transcripts
Business News Top © 2024-2025